A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Exclusion Criteria

• •Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
• •Presence of a condition or abnormality that in the opinion of the Investigators would compromise the safety of the patient or the quality of the data.
• •Current substance use disorder, psychotic disorder, bipolar disorder, or eating disorder.
• •Current use of recreational cannabis, medical cannabis, or hemp-derived cannabinoid products more frequently than 1x/month; positive urine delta-9 tetrahydrocannabinol (THC) test.
• •Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease.
• •Current use of valproate (due to potential for drug-drug interactions).
• •Currently enrolled in other research studies or clinical trials involving therapeutic interventions.
• •Subjects with serum transaminase (ALT, AST, and total bilirubin) levels \>3 times upper limit of normal (UNL) \<24 hours prior to day 1 of treatment.
• •Contraindication to MRI such as non-MR conditional medical devices or ferrous retained foreign bodies.